Positive Patient Stories™

Investor Overview

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.3 (2.53%)
Data as of 10/26/16 2:41 p.m. ET

Latest News

Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016
Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2, 2016
Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens
Paratek to Ring Nasdaq Closing Bell Recognizing 20th Anniversary
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.